Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $701,207.00 |
|---|---|
| Enterprise Value | $-4,776,343.00 |
| Earnings per Share | $-25.99 |
| Beta | 0.58 |
| Outstanding Shares | 845,439 |
| P/E Ratio | -0.03 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | 0.17 |
| Enterprise Value to Revenue | -16.13 |
| Enterprise Value to EBIT | 0.29 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.54 |
| Debt to Equity | 0.59 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 8.34%▲ 7.53% |
|---|---|
| Total Invested | $87,429▲ 181.67% |
| Investors Holding | 5▲ 1.00% |
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelera...